Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Demonstrate Non-inferiority of Men-C Immune Response of Hib-MenC With Infanrix-IPV Versus a Licensed Men-C Vaccine With Pediacel When Given at 2, 3, 4 Months and the Immunogenicity of Hib-MenC When Given as a Booster Dose at 12-15 Months

Next Previous
Trial Profile

Demonstrate Non-inferiority of Men-C Immune Response of Hib-MenC With Infanrix-IPV Versus a Licensed Men-C Vaccine With Pediacel When Given at 2, 3, 4 Months and the Immunogenicity of Hib-MenC When Given as a Booster Dose at 12-15 Months

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 27 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Hib-meningococcal vaccine group C conjugate (Primary) ; DTaP poliovirus vaccine; Hib-DTaP-poliovirus vaccine; Measles mumps and rubella virus vaccine-(Priorix); Meningococcal vaccine group C conjugate
  • Indications Diphtheria; Haemophilus infections; Meningococcal group C infections; Neisseria infections; Pertussis; Poliomyelitis; Tetanus
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline; GSK

    • Most Recent Events

    • 01 Nov 2008 Primary endpoint 'Antibody levels' has been met.
    • 01 Nov 2008 Primary endpoint 'Seroprotection rate' has been met.
    • 01 Nov 2008 Results published in Archives of Disease in Childhood, according to 1124825.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top